{
    "2021-09-26": [
        [
            {
                "time": "",
                "original_text": "康泰生物大股东倡议员工增持自身减持套现近1亿元，回复问询称未配合减持 问询",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "大股东",
                        "员工增持",
                        "减持套现",
                        "问询"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业：海外新冠治疗药物有望Q4陆续获批 重点推荐相关CDMO标的",
                "features": {
                    "keywords": [
                        "医药生物",
                        "海外",
                        "新冠治疗药物",
                        "Q4获批",
                        "CDMO"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}